Business Wire

Fluence Supporting Premium Dutch Floriculture Brands to Future-Proof and Increase Sustainability

9.2.2023 16:30:00 EET | Business Wire | Press release

Share

Fluence, a leading global provider of energy-efficient LED lighting solutions for floriculture, medicinal cannabis and food production, is supporting sustainability and operational cost efficiency amid volatile energy market conditions in Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230209005211/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Orchids under Fluence LED lighting at Bernhard Kwekerijen, a rose, orchid and patio plant nursery. (Photo: Business Wire)

Europe’s soaring energy prices have affected many growers in countries like the Netherlands that primarily produce electricity via the gas-powered cogeneration method. Gas prices have historically balanced between €15 and €20 per megawatt-hour (MWh) but peaked at over €300 per MWh in 2022 because of volatility due to supply, storage and weather conditions. Current energy prices have dropped to €60 per MWh, remaining roughly three times higher than what many growers planned to pay for electricity.

Leading floriculture companies dedicated to delivering high-quality products to customers—including Bernhard Kwekerijen, Moerman Lilium, Deliflor Chrysanten, Beyond Chrysant and Ten Have Plant—have made the switch from high-pressure sodium (HPS) fixtures to Fluence's LED technology, which increase photon output and energy efficiency.

“As they confront the unpredictability of Europe’s energy market, Dutch cultivators are increasingly focused on future-proofing their cultivation strategies by decreasing their dependency on fossil energy and engaging in sustainable practices,” said Gert-Jan Goes, horticulture specialist at Fluence. “Fluence’s RAPTR light fixture and Wireless Flex Dimming control panel help growers maximize their return on investment while increasing control over light intensity while increasing control over light intensity and dimming up and down creates maximum flexibility to profit from highly fluctuating energy markets.”

Moerman Lilium, a lily cultivator, has 13 hectares of crops under full LED lighting and uses Fluence’s RAPTR fixtures regulated via a Wireless Flex Dimming controller. The company—which monitors European energy prices very closely—uses Fluence solutions to react quickly and modify light intensity based on market conditions. Moerman Lilium expects to save at least 45% on electricity costs with the investment in Fluence’s LED lighting solutions.

“LED lighting allows us to be more energy efficient while adjusting our electricity use based on fluctuations in energy prices,” said Jan Moerman, co-owner of Moerman Lilium. “Switching to Fluence LEDs has saved us money and given us more flexibility in a constantly changing energy market.”

Deliflor Chrysanten is the global market leader in breeding and propagating chrysanthemum varieties. The company was in search of a high-efficiency lighting solution featuring additional green light in the spectrum for better visibility and growth. Deliflor Chrysanten opted for Fluence’s RAPTR Broad R8 spectrum in their recently renewed breeding facilities to guarantee the best circumstances for their newest varieties. The first flower trial grown under the Fluence’s fixtures turned out very successful last January. Beyond Chrysant, a leading Dutch chrysanthemum cultivator, also chose Fluence’s RAPTR solution for its customizability and high-visibility spectrum that create increased efficiency in its integrated crop management practices. Installing Fluence’s LED technology has allowed Beyond Chrysant to gain greater control over the oscillating European energy market. The company was recently named a finalist for Stichting Tuinbouw Ondernemersprijs’ “2023 Horticultural Entrepreneur Award.”

Even in hybrid lighting environments, growers are seeing the benefits of using LED technology. Bernhard Kwekerijen—a rose, orchid and patio plant nursery—promotes a carbon-neutral and sustainable operation by using geothermal heat and its own photovoltaic field of solar panels to generate energy. By incorporating Fluence’s RAPTR fixtures alongside legacy HPS solutions and maximizing light control with Wireless Flex Dimming, Bernhard Kwekerijen has elevated CO2-neutral cropping in its Phalaenopsis cultivation.

“Fluence’s technology stands out because it affords the greatest flexibility in modifying energy consumption and light intensity according to energy market price instability,” said Dennis Raadschelders, strategic account manager for commercial agriculture at Fluence. “Our Dutch floriculture growers have harnessed control over operational expenses without sacrificing product quality by emitting more light when energy prices are low, and quickly reducing light when energy prices rise.”

Fluence’s team of horticultural experts work closely alongside partners to design lighting programs based on operations-specific crop and sustainability goals. Ten Have Plant, one of the oldest potted plant nurseries in Westland, selected Fluence as its lighting solutions partner to achieve better crop and root development in addition to reducing costs and increasing energy efficiency. Ten Have Plant worked with Fluence’s horticulture team to design a lighting plan to produce cyclamen for half the year and campanula in the other half, selecting VYPR 3p Broad R6 top lights to gain control over seasonal light conditions and electricity consumption year-round.

“Fluence LED fixtures are widely used by leading cannabis, commercial agriculture and floriculture companies across Europe, demonstrating the flexibility and universal benefit in transitioning to LED technology,” said David Cohen, CEO of Fluence. “We are excited to work with Dutch floriculture growers who have deep roots in the industry and support their management of environmental conditions, sustainable operations and the highest quality crops.”

For more information on Fluence, visit www.fluence.science.

About Fluence

Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For EMEA,
Silvia Nagyova
silvia.nagyova@fluence-led.com
+49 160 93335045

For North America,
Callie Neatherlin
callie@redfancommunications.com
512-439-9720

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye